The discrepancy between the different tenofovir prodrugs leading to mixed effectiveness is unexplained yet deserves further analysis. Given the limited resources to screen potential antivirals, and the challenges for implementing clinical trials which are the definitive source of evidence, theoretical modeling can help accelerate drug discovery especially, particularly when coupled with experimental data.